Thursday, May 26, 2016

Molecular mechanisms of statin intolerance

Your doctor should be able to give you the exact percentage risks of developing these side effects. How many of their patients have discontinued statins because of side effects?
http://www.termedia.pl/Molecular-mechanisms-of-statin-intolerance,19,27579,0,1.html

Anna Gluba-Brzozka, Beata Franczyk, Peter P. Toth, Jacek Rysz, Maciej Banach

Arch Med Sci 2016; 12, 3: 645–658
DOI (digital object identifier): 10.5114/aoms.2016.59938
Statins reduce cardiovascular morbidity and mortality in primary and secondary prevention. Despite their efficacy, many persons are unable to tolerate statins due to adverse events such as hepatotoxicity and myalgia/myopathy. In the case of most patients, it seems that mild-to-moderate abnormalities in liver and muscle enzymes are not serious adverse effects and do not outweigh the benefits of coronary heart disease risk reduction. The risk for mortality or permanent organ damage ascribed to statin use is very small and limited to cases of myopathy and rhabdomyolysis. Statin-induced muscle-related adverse events comprise a highly heterogeneous clinical disorder with numerous, complex etiologies and a variety of genetic backgrounds. Every patient who presents with statin-related side effects cannot undergo the type of exhaustive molecular characterization that would include all of these mechanisms. Frequently the only solution is to either discontinue statin therapy/reduce the dose or attempt intermittent dosing strategies at a low dose.

No comments:

Post a Comment